More on ENTA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.47 |
|
|||
| Open | $11.65 | ||||
| 52 Wk High | $34.49 | ||||
| 52 Wk Low | $20.39 | ||||
| Day High | $11.65 | ||||
| Day Low | $10.95 | ||||
| P/E | N/A | ||||
| EPS | $-3.18 | ||||
| Volume | 215,413 | ||||
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek⢠2026
- H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
- H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
- Enanta Pharmaceuticals to Participate in September Investor Conferences
- Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Deep Track Capital, LP
- Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
- Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30
- Form 8-K ENANTA PHARMACEUTICALS For: Aug 10
- Enanta Pharma (ENTA) Misses Q3 EPS by 17c
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Entities mentioned with ENTA
- Earnings | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Twitter | View Related Stories »
- JPMorgan | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
